European Medicines Agency maintains dosage recommendations for pandemic H1N1 vaccines

23 October 2009

The European Medicines Agency (EMEA) has concluded that its recommendations adopted in September, that the three licensed H1N1 vaccines be preferably used as two doses, at least three weeks apart, be maintained. This follows the recent meeting (19-22 October 2009) of the EMEA’s Committee for Medicinal Products for Human Use.

The Committee will review further clinical trial data as they become available and, as a result, the dosing recommendations may change in the future. 

Download EMEA Press Release